PULM Pulmatrix, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1574235 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY32.3%
TTM EPS YoY32.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-125.1%
Net margin-122.5%
FCF margin-142.4%
EBITDA margin-123.7%
Returns
ROE-71.0%
ROA-43.5%
ROIC (approx.)—
Asset turnover0.36x
Leverage & solvency
Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio5.3%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $7.81M | $7.30M | $6.07M | $5.17M |
| R&D expense | $38,000 | $7.17M | $15.52M | $18.24M | $15.38M |
| SG&A expense | $5.13M | $7.79M | $6.52M | $6.78M | $6.38M |
| Operating income | -$5.17M | -$9.76M | -$14.74M | -$18.95M | -$20.17M |
| Income tax | $0 | — | — | — | — |
| Net income | -$5.16M | -$9.56M | -$14.12M | -$18.84M | -$20.17M |
| EBITDA | — | -$9.66M | -$14.61M | -$18.79M | -$20.00M |
| EPS (basic) | -1.41 | -2.62 | -3.87 | -5.46 | -8.63 |
| EPS (diluted) | -1.41 | -2.62 | -3.87 | -5.46 | -8.63 |
| Weighted avg. shares (diluted) | 3.65M | 3.65M | 3.65M | 3.45B | 2.71M |
| Banking | |||||
| Net interest income | — | $467,000 | $867,000 | $309,000 | $7,000 |
| Balance sheet | |||||
| Cash & equivalents | $4.09M | $9.52M | $19.17M | $35.63M | $53.84M |
| Receivables | — | — | $928,000 | $1.30M | $67,000 |
| Current assets | $4.13M | $9.92M | $20.84M | $38.15M | $54.78M |
| PP&E, net | — | — | $1.16M | $235,000 | $321,000 |
| Total assets | $4.14M | $9.94M | $33.96M | $40.95M | $58.82M |
| Current liabilities | $329,000 | $929,000 | $3.91M | $5.02M | $4.44M |
| Total liabilities | $329,000 | $996,000 | $15.96M | $9.84M | $11.37M |
| Shareholders' equity | $3.81M | $8.95M | $18.00M | $31.11M | $47.45M |
| Shares outstanding | 3.65M | 3.65M | 3.65M | 3.64M | 3.22M |
| Cash flow statement | |||||
| Operating cash flow | -$5.43M | -$10.72M | -$15.98M | -$19.36M | -$19.73M |
| Capital expenditure | — | $398,000 | $676,000 | $86,000 | $144,000 |
| Free cash flow | — | -$11.11M | -$16.66M | -$19.44M | -$19.87M |
| Investing cash flow | — | -$398,000 | -$676,000 | -$86,000 | -$144,000 |
| Financing cash flow | — | — | $53,000 | $1.23M | $43.48M |
| Depreciation & amortization | — | $106,000 | $134,000 | $162,000 | $169,000 |
| Stock-based compensation | $25,000 | $511,000 | $954,000 | $1.11M | $1.16M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.